Greater cumulative exposure to a pro‐inflammatory diet is associated with higher metabolic syndrome score and blood pressure in young Mexican adults

Background:Evidence of components of metabolic syndrome including. Obesity dyslipidemia, abnormal glucose tolerance rate and hypertension are associated with fibromyalgia. Adrenocorticotrophic hormone (ACTH) is reported to be significantly higher in fibromyalgia patients, and it causes obesity, high blood pressure.Objectives:This study aimed to assess the serum level of ACTH as a contributing as well as a discriminator hormone in newly diagnosed fibromyalgia women presented with variable components of metabolic syndrome.Methods:This cross-sectional study comprised 100 women with newly diagnosis fibromyalgia and 30 apparent healthy women served as control from Kurdistan region-Iraq. Clinical data including the score of fibromyalgia impact questionnaire-revised (FIQR), tender point, body mass index, waist circumference, blood pressure and fasting serum levels of glucose and lipid profile, and ACTH level. The score of metabolic syndrome was calculated using the formula:Results:Compared to the controls, the Fibromyalgia women displayed significantly higher values of waist circumference (88.9 ± 5.7cm versus 87.1 ± 2.7cm, p=0.019), systolic blood pressure (136.1 ±13.5mmHg versus 131.4 ± 7.1, p=0.014), metabolic syndrome score (3.10 ±0.25 versus 3.03±0.19, p=0.039), and serum ACTH levels (16.66 ± 3.23pg/ml versus 14.42 ± 2.18pg/ml. p<0.001). Serum ACTH levels significantly and inversely correlated with the total score of the FIQR (r = - 0.320. p=0.001) and number of tender points (r= - 0.374, p<0.001). Metabolic syndrome score is significantly and inversely correlated with the total FIQR score (r = - 0.296, p=0.003). Multivariable regression analysis using showed that serum level of ACTH is a significant (p= predictor of 19.7% of fibromyalgia patients (Figure 1), and it is a significant (p=0.007) discriminator of tender points as the area under the curve is 0.325(95%C.I.: 0.212-0.438) (Figure 2).Figure 1.Multivariable regression analysis withposthocANOVA test showed significant correlations between serum level adrenocorticotrophic hormone as a dependent variable with the score s of fibromyalgia impact questionnaire and metabolic syndrome, and the number of tender points. R=0.443, F=7.777, P<0.001, prediction 19.7%),Figure 2.serum level of ACTH (cutoff level ≥14.5pg/ml, sensitivity=72%, specificity=50%) as a discriminator of the tender points (AUC95% C.I: 0.325[0.212-0.438], p=0.007), score of fibromyalgia symptoms (AUC95% C.I: 0.474[0.313-0.581], p=0.409), and metabolic syndrome score (AUC95% C.I: 0.546[0.423-0.668], p=0.480)Conclusion:Fibromyalgia women responded to the stress of pain by increasing the serum level of ACTH which effectively improves the clinical feature of fibromyalgia symptoms, but at the same time elevates the score of metabolic syndrome. Therefore, assessment of serum level of ACTH can serve as a predictor and discriminator of fibromyalgia comorbidity.References:[1]Acosta-Manzano P, Segura-Jiménez V, Estévez-López F, Álvarez-Gallardo IC, Soriano-Maldonado A, Borges-Cosic M, Gavilán-Carrera B, Delgado-Fernández M, Aparicio VA. Do women with fibromyalgia present higher cardiovascular disease risk profile than healthy women? The al-Ándalus project. Clin Exp Rheumatol. 2017; 35 Suppl 105(3):61-67.[2]Marwan S.M. Al-Nimer, Talar A.M. Mohammad, Avin M.A. Maroof. Dysfunction of anterior pituitary gland in women patients with recent fibromyalgia: A cross-sectional observational study. Electron J Gen Med 2018;15(4):em58[3]Soldatovic I, Vukovic R, Culafic D, Gajic M, Dimitrijevic-Sreckovic V. siMS score: simple method for quantifying metabolic syndrome. PLoS One. 2016; 11(1):e0146143Disclosure of Interests: :None declared

Download Full-text

Uric Acid: An Overlooked, Inexpensive Biomarker of Metabolic Syndrome (P10-068-19)

Current Developments in Nutrition ◽

10.1093/cdn/nzz034.p10-068-19 ◽

2019 ◽

Vol 3 (Supplement_1) ◽

Cited By ~ 1

Author(s):

Maribel Barragan ◽

Viridiana Luna ◽

Juan Manuel Vargas-Morales ◽

Celia Aradillas-Garcia ◽

Margarita Teran-Garcia

Keyword(s):

Risk Factors ◽

Blood Pressure ◽

Metabolic Syndrome ◽

Uric Acid ◽

Serum Uric Acid ◽

San Luis ◽

San Luis Potosi ◽

Mexican Adults ◽

Males And Females ◽

San Luis Potosí

Abstract Objectives Elevated serum uric acid (HUA) levels have been shown to have a positive correlation with metabolic syndrome (MetS) risk factors. In countries where rates of MetS continue to increase, such as Mexico, it is important to identify reliable and inexpensive markers that will aid in predicting the development of MetS. Our aim was to evaluate the association between serum uric acid (UA) and MetS risk factors in young Mexican adults. Risk factors include glucose (GLU), systolic blood pressure (SBP), diastolic blood pressure (DBP), waist circumference (WC), triglycerides (TG), high-density lipoprotein (HDL), and body mass index (BMI). Methods Mexican college applicants involved in the Universities of San Luis Potosí and Illinois: Multidisciplinary Investigation on Obesity, Genetics and Socio-environment (UP AMIGOS) cohort (ages 18–25, n = 747, 56% female) underwent a health screening following an overnight fast. Fasting blood samples, anthropometric measurements, and blood pressure were collected. According to the literature, HUA levels are defined as ≥7 and ≥6 mg/dL for males and females, respectively. T-tests were conducted to compare mean differences of MetS risk components between individuals with and without HUA levels. Analyses were conducted separately by sex. Results The mean ± SD of UA was 5.73 ± 1.32 mg/dL and 4.39 ± 1.19 mg/dL for males and females, respectively. Males and females with HUA had significantly higher TG, and WC, and lower HDL (all P < 0.001). HUA was positively correlated with WC (R2 = 0.331, SBP (R2 = 0.151), DBP (R2 = 0.176), GLU (R2 = 0.863), TG (R2 = 0.424) and BMI (R2 = 0.363). In contrast, HDL was negatively correlated with HUA (R2 = -0.277), as hypothesized. All Pearson correlations were adjusted for age and sex and statistically significant (P < 0.05). Conclusions Serum UA has a strong correlation with MetS risk factors in young Mexican adults. Routine monitoring of serum UA could be utilized as an inexpensive early predictor of MetS, which would allow for early interventions to aid in preventing cardiovascular disease and type 2 diabetes. Funding Sources This study was funded by the University of Illinois at Urbana-Champaign and the USDA National Institute of Food and Agriculture, Hath Projects to M.T.-G. Funding was also provided by the Univerdidad Autonoma de San Luis Potosí to support C.A.-G.

Download Full-text

Metabolic syndrome score and ambulatory blood pressure in untreated essential hypertension

Blood Pressure Monitoring ◽

10.1097/01.mbp.0000170921.55412.02 ◽

2005 ◽

Vol 10 (4) ◽

pp. 175-180 ◽

Cited By ~ 12

Author(s):

Cesare Cuspidi ◽

Stefano Meani ◽

Cristiana Valerio ◽

Eleonora Catini ◽

Veronica Fusi ◽

...

Keyword(s):

Blood Pressure ◽

Metabolic Syndrome ◽

Essential Hypertension ◽

Ambulatory Blood Pressure ◽

Metabolic Syndrome Score

Download Full-text

Heritability of Serum Resistin and Its Genetic Correlation with Insulin Resistance-Related Features in Nondiabetic Caucasians

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2005-2715 ◽

2006 ◽

Vol 91 (7) ◽

pp. 2792-2795 ◽

Cited By ~ 88

Author(s):

Claudia Menzaghi ◽

Angelo Coco ◽

Lucia Salvemini ◽

Ryan Thompson ◽

Salvatore De Cosmo ◽

...

Keyword(s):

Insulin Resistance ◽

Blood Pressure ◽

Metabolic Syndrome ◽

Genetic Correlations ◽

Resistance Index ◽

Variance Component Analysis ◽

Phenotypic Characterization ◽

Study Cohort ◽

The Metabolic Syndrome ◽

Metabolic Syndrome Score

Abstract Context: Serum levels of resistin are believed to modulate insulin resistance in humans. Objective: The aim of this study was to investigate whether serum resistin levels are genetically controlled and whether this control is shared with other insulin resistance traits. Design and Methods: The study cohort included 264 nondiabetic probands, Caucasian from Italy, and their 473 adult family members. Phenotypic characterization included anthropometric variables, blood pressure, fasting glucose and insulin, lipid profile, and resistin levels. Genotypes were determined at position g.−420C→G (rs1862513), IVS2+181G→A (rs3745367), and GAT(n) polymorphisms of the resistin (RETN) gene. Results: In the 264 unrelated probands, resistin levels were significantly (P < 0.01) correlated with adiposity, blood pressure, C-reactive protein, and the metabolic syndrome score. In a variance component analysis of the 264 probands and their 473 relatives, about 70% of the observed variation of serum resistin levels was heritable (P < 0.0001). A small, but significant (P = 0.004) proportion of this variance was explained by the G→A variation at position IVS2+181 of the RETN gene. Significant genetic correlations (P < 0.05) were observed between resistin and body mass index (ρg = 0.30), waist circumference (ρg = 0.32), the insulin resistance index HOMAIR (ρg = 0.28), and the metabolic syndrome score (ρg = 0.35). Conclusions: These data indicate that serum resistin is highly heritable and has some common genetic background with traits related to insulin resistance, reinforcing the hypothesis that this adipokine may play a pathogenic role in insulin resistance-related abnormalities, including type 2 diabetes and cardiovascular disease.

Download Full-text

METABOLIC SYNDROME IN DIALYSIS PATIENTS

Journal of Medicine and Pharmacy ◽

10.34071/jmp.2016.5.1 ◽

2016 ◽

pp. 7-11

Author(s):

Vinh Phu Hoang ◽

Tam Vo ◽

Van Tien Le ◽

Thi Hoai Huong Vo

Keyword(s):

Blood Pressure ◽

Metabolic Syndrome ◽

Renal Failure ◽

Chronic Renal Failure ◽

Artificial Kidney ◽

Dialysis Patients ◽

Cross Sectional ◽

Average Value ◽

The Metabolic Syndrome ◽

End Stage

Objective: To review disorders elements of the metabolic syndrome in patients with end-stage chronic renal failure on dialysis cycle. Materials and methods: A cross sectional descriptive study of 85 patients including end-stage chronic renal failure in dialysis cycle from 5/2015 - 9/2016 at the Department of Artificial Kidney, Hue Central Hospital. Results: The prevalence of metabolic syndrome in dialysis patients was 37.65%. The prevalence of abdominal obesity was 30.6%; The prevalence of hypertension was 72.9%, the average value systolic blood pressure and diastolic blood pressure were 142.24 ± 27.53, 80.35 ± 12.48 mmHg; The prevalence of hyperglycemia was 28%, the average value blood glucose was 4.9 ± 1.19 mmol/l; The prevalence of triglyceride increase was 34.1%, the average value triglyceride was 1.59 ± 0.84 mmol/l. The prevalence of HDL-C increase was 47.1%, the average value HDL-C was 1.24 ± 0.33 mmol/l. Conclusion: The prevalence of metabolic syndrome in dialysis patients is very high, in which hypertension and HDL disturbances are the highest. Key words: chronic renal failure, dialysis, metabolic syndrome

Download Full-text

Comparative Effect of Telmisartan vs Lisinopril on Blood Pressure in Patients of Metabolic Syndrome

Endocrine Metabolic & Immune Disorders - Drug Targets ◽

10.2174/1871530314666141128154152 ◽

2015 ◽

Vol 15 (1) ◽

pp. 64-70 ◽

Cited By ~ 1

Author(s):

Pradip N. Gore ◽

Vandana A. Badar ◽

Mrunalini M. Hardas ◽

Varsha J. Bansode

Keyword(s):

Blood Pressure ◽

Metabolic Syndrome ◽

Comparative Effect

Download Full-text

Association between polymorphism at IGF-1 rs35767 gene locus and long-term decline in renal function: a Japanese retrospective longitudinal cohort study

BMC Nephrology ◽

10.1186/s12882-021-02408-9 ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Kosuke Honda ◽

Satoru Kuriyama ◽

Kimiyoshi Ichida ◽

Tomoko Nakano ◽

Naoki Sugano ◽

...

Keyword(s):

Blood Pressure ◽

Metabolic Syndrome ◽

Renal Function ◽

Uric Acid ◽

Cohort Study ◽

Serum Uric Acid Level ◽

Human Growth ◽

Longitudinal Cohort Study ◽

Longitudinal Cohort

Abstract Background Insulin-like growth factor-1 (IGF-1) acts on glucose and protein metabolism and human growth and also influences blood pressure and renal function. This study investigated whether the single-nucleotide polymorphism of IGF-1, rs35767, plays a role in metabolic syndrome indicators, including blood pressure, glucose metabolism, uric acid levels, and renal function. Methods In this retrospective longitudinal cohort study, blood samples from 1506 Japanese individuals were collected and used for genotyping for variant rs35767: T > C in the IGF-1 upstream promoter. Data were analyzed to identify associations between IGF-1 genotypes and patient biochemical parameters, including the components of metabolic syndrome and the long-term change in renal function. Results The cohort rs35767 genotypes included 650 CC carriers (43.2%), 687 TC carriers (45.6%), and 169 TT carriers (11.2%). Multiple regression analysis revealed no association between IGF-1 genotype and blood pressure, glycated hemoglobin level, and serum uric acid level. However, in females, blood pressure was negatively correlated with the TT genotype. Longitudinal observation revealed that the decline in eGFR over 10 years was greater in TT (− 18.51 ± 1.04 mL/min/1.73m2) than in CC carriers (− 16.38 ± 0.52 mL/min/1.73m2; P < 0.05). Conclusion The present study suggests that renal function declines faster in individuals with the TT genotype at the IGF-1 rs35767 locus than in those with the CC genotype, suggesting that the TT genotype is associated with the long-term chronological decline in renal function.

Download Full-text

Metabolic Syndrome Features and Excess Weight Were Inversely Associated with Nut Consumption after 1-Year Follow-Up in the PREDIMED-Plus Study

Journal of Nutrition ◽

10.1093/jn/nxaa289 ◽

2020 ◽

Vol 150 (12) ◽

pp. 3161-3170

Author(s):

Alicia Julibert ◽

Maria del Mar Bibiloni ◽

Laura Gallardo-Alfaro ◽

Manuela Abbate ◽

Miguel Á Martínez-González ◽

...

Keyword(s):

Blood Pressure ◽

Metabolic Syndrome ◽

Energy Intake ◽

Disease Risk ◽

Cardiovascular Disease Risk ◽

Virgin Olive Oil ◽

Hdl Cholesterol ◽

Excess Weight ◽

Study Cohort

ABSTRACT Background High nut consumption has been previously associated with decreased prevalence of metabolic syndrome (MetS) regardless of race and dietary patterns. Objectives The aim of this study was to assess whether changes in nut consumption over a 1-y follow-up are associated with changes in features of MetS in a middle-aged and older Spanish population at high cardiovascular disease risk. Methods This prospective 1-y follow-up cohort study, conducted in the framework of the PREvención con DIeta MEDiterránea (PREDIMED)-Plus randomized trial, included 5800 men and women (55–75 y old) with overweight/obesity [BMI (in kg/m2) ≥27 and <40] and MetS. Nut consumption (almonds, pistachios, walnuts, and other nuts) was assessed using data from a validated FFQ. The primary outcome was the change from baseline to 1 y in features of MetS [waist circumference (WC), glycemia, HDL cholesterol, triglyceride (TG), and systolic and diastolic blood pressure] and excess weight (body weight and BMI) according to tertiles of change in nut consumption. Secondary outcomes included changes in dietary and lifestyle characteristics. A generalized linear model was used to compare 1-y changes in features of MetS, weight, dietary intakes, and lifestyle characteristics across tertiles of change in nut consumption. Results As nut consumption increased, between each tertile there was a significant decrease in WC, TG, systolic blood pressure, weight, and BMI (P < 0.05), and a significant increase in HDL cholesterol (only in women, P = 0.044). The interaction effect between time and group was significant for total energy intake (P < 0.001), adherence to the Mediterranean diet (MedDiet) (P < 0.001), and nut consumption (P < 0.001). Across tertiles of increasing nut consumption there was a significant increase in extra virgin olive oil intake and adherence to the MedDiet; change in energy intake, on the other hand, was inversely related to consumption of nuts. Conclusions Features of MetS and excess weight were inversely associated with nut consumption after a 1-y follow-up in the PREDIMED-Plus study cohort. This trial was registered at isrctn.com as ISRCTN89898870.

Download Full-text